Peptide Development Readiness: From Series A to IND

What “peptide development readiness” actually means

Peptide development readiness is not a stage label. It is the set of evidence artifacts a program can hand to an investor, a partner or a regulator without caveat. A program is ready when its synthesis history, scale-up data, modification controls, analytical package and process decisions all survive scrutiny at the same time.

The September 2026 TwoStep Therapeutics news is a useful observational anchor: a Series A financing and an IND clearance for TS-104, described publicly as a peptide-drug conjugate that pairs an integrin-binding peptide with MMAE, with Phase 1 expected later in 2026. What that record does not disclose is the underlying CMC data. The financing and the clearance are visible; the synthesis reproducibility, the scale-up runs and the analytical validation behind them are not.

That gap is why this guide is built from primary regulatory documents and practitioner evidence rather than from one company’s filings. The framework below organises readiness into five gates, from sequence to IND-ready candidate, each producing a specific artifact you can demand of your own program.

Kle Takeaway: Readiness is assessable before a regulator assesses it. If you cannot produce the artifact behind a gate, that gate is not closed, regardless of how far the program has advanced.

Prerequisites: what you need before assessing readiness

Sèvis The five gates that follow are only as useful as the documents you bring to them. Before running a self-assessment, assemble four things.

Current batch records and certificates of analysis. Not the summary table from a slide deck: the actual batch records, with lot numbers, yields, and the analytical results as reported.

The analytical methods and their validation status. For each method, know whether it is qualified, validated, or still in development. A method that has not been validated cannot support a release specification, and the gap will surface at Gate 4.

The target product profile, intended route, and dose. These drive the endotoxin and sterility limits you will apply later, so a readiness review without them is incomplete.

Familiarity with the primary documents the gates reference. The FDA’s own CMC content requirements for an IND set out the section-by-section Phase 1 expectations, including the 21 CFR 312.23(a)(7) chemistry, manufacturing, and controls content. The ICH and USP standards named throughout, ICH Q2(R2), ICH Q6B, ICH Q1A(R2), USP <71>, and USP <85>, are the reference points for validation, specifications, stability, sterility, and bacterial endotoxins respectively. The FDA page was read directly for this article and confirms those Phase 1 contents; the ICH PDFs were not readable in this run, so treat them as standards to consult rather than as text quoted here.

Assume you are comfortable with RP-HPLC and UPLC terminology, can read a chromatogram, and can follow LC-MS data without a translation layer. If that is not you, bring someone who can. A realistic self-assessment across all five gates takes two to three days of focused work, most of it spent locating documents rather than interpreting them.

Before you start: the most common delay is not a technical gap. It is discovering mid-assessment that a method was never validated or a batch record is missing.

Gate 1: Prove synthesis reproducibility

By the end of this gate you should be able to show that the same sequence, made twice, gives the same impurity profile within limits you defined in advance. Reproducibility is the first thing a partner or reviewer probes, because a process that cannot repeat cannot be validated.

Start by fixing how you measure. Purity is defined by RP-HPLC or UHPLC as the percentage of target peptide relative to impurities absorbing at 220 nm, the peptide-bond absorption basis, and the principal impurities are deletion sequences generated during synthesis (GenScript, retrieved 2026-08-03). Then set lot-to-lot acceptance criteria against the grade the program actually needs, not the best grade available: published grades run ≥75% immuno, ≥85% biochemistry, ≥95% high-purity and ≥98% industrial, and lot-to-lot variability rises as purity falls, especially below 80% (GenScript, retrieved 2026-08-03). Treat those grades as vendor commercial categories, not regulatory specifications.

The failure mode is a program that reports one best-batch purity and cannot reproduce it. Qualify a supplier on a single 98% lot and scale-up may reveal that the routine grade is 85%, with visible drift between batches.

Gate 2: De-risk scale-up before you need it

By the end of this gate, you should be able to say whether your route survives the move from milligram to kilogram, and point to data rather than a vendor’s confidence. Scale-up is where a workable research route quietly becomes an uneconomic or non-reproducible one, so the question is not whether a CDMO can make more material, but whether it has already made it.

Ask where solid-phase synthesis stops scaling cleanly. Neuland Labs puts straightforward linear SPPS at a practical limit of roughly 30 pou 40 residues, and reports that modified peptides, meaning cyclic, lipidated or conjugated sequences, need to hold at least 95% purity at kilogram scale, which in practice means multi-step preparative HPLC and controlled lyophilization (Neuland Labs, 2025). Impurity thresholds usually sit at or below 0.1% and require justification, not assumption.

The failure modes practitioner literature names at scale are specific and worth testing against your own sequence: aggregation from extended coupling cycles, side reactions, yield decline as the chain lengthens, near-linear consumption of resin, protected amino acids and solvent, purification complexity, hold-time degradation losses, and quality deviations such as stereochemistry change, purity loss and batch failure that get magnified at higher volume (Neuland Labs, 2025).

One honest caveat on the evidence base. The quantitative peptide synthesis scale-up benchmarks available to this assessment come from vendor and legacy literature. The large-scale SPPS figures published by Andersson and colleagues in 2000 are legacy references and were not page-verified here, so treat them as background rather than as current performance data. Demand your own numbers: batch records, in-process controls, and at least one demonstrated campaign at the scale you intend to file.

Gate 3: Control modifications deliberately

By the end of this gate you should be able to show that every non-natural modification in your candidate is specified, controlled and analytically confirmed, not assumed. A modification made is not a modification controlled.

Enumerate each modification, name the attribute it changes, and pair it with the method that confirms it. Cyclization alters conformational stability and is confirmed by peptide mapping and NMR where identity needs orthogonal support. Lipidation and PEGylation change hydrophobicity, aggregation behaviour and half-life, and are confirmed by LC-MS/HRMS and amino acid analysis. Conjugation is the case where a peptide program’s chemistry and its analytics most often diverge, because the conjugate’s components each need their own control.

TS-104 illustrates the point. BusinessWire describes TS-104 as a PIP integrin-binding peptide conjugated to MMAE, so the readiness question is not only peptide purity but conjugate consistency. Peptid sentetik The public record does not disclose the conjugation chemistry, the drug-to-peptide ratio control or the release specifications, so those remain inferred rather than evidenced. Konsènan

The failure mode is a modification introduced for potency that silently changes the impurity profile or the stability of the peptide, discovered only when the peptide analytical package is assembled.

Gate 4: Build the analytical package

By the end of this gate you should hold a method-by-attribute package: one row per release attribute, one named procedure per row, and a validation status for each. The package is the evidence layer every earlier gate depends on, because a purity number alone tells a reviewer nothing about identity, counterion, residual solvents or endotoxin.

Start from the FDA’s own CMC content requirements for an IND, which specify structure and identity evidence, the manufacturer, a general method of preparation with reagents, solvents and catalysts plus a flow diagram, acceptable limits and analytical methods for identity, strength, quality and purity, and stability information (U.S. Food and Drug Administration, retrieved 2026-09-18). The agency’s stated bar is that sufficient information “should be submitted to assure the proper identification, quality, pite, and strength of the investigational drug.” NMR, IR and UV are the conventional identity methods, HPLC carries purity and impurities, and certificates of analysis are expected alongside.

Then attach validation expectations to each row. ICH Q2(R2) sets the validation characteristics by procedure purpose: assay and potency procedures need specificity, accuracy, precision, linearity, range and robustness, with LOD and LOQ generally not expected; quantitative impurity procedures add LOD and LOQ; limit tests centre on specificity and LOD; identity centres on specificity and selectivity. The acceptance ranges most programs apply are roughly 98.0–102.0% recovery for assay accuracy, %RSD ≤2% for assay repeatability, 80–120% recovery for impurity accuracy, %RSD ≤5% for impurity precision and %RSD ≤10% at the LOQ. Treat those ranges as a starting convention rather than a fixed requirement, and confirm the parameter sets against the guideline text itself before you commit them to a specification.

For the specification itself, ICH Q6B’s specification framework is the useful template even for a synthetic peptide: identity via a highly specific test or more than one if needed, purity and impurities via method-dependent tests that may require a combination of methods, and potency via an assay reflecting biological activity. Acceptance criteria should follow process capability, method performance, product characterization and clinical relevance rather than a universal test list.

Impurity limits deserve their own row. In the FDA-adjacent framework commonly applied to synthetic peptides, peptide-related impurities present in both test and reference product should be no higher than the comparator, new peptide-related impurities above roughly 0.10% should be identified and justified, and new impurities above 0.5% are generally not acceptable. That framework was not read directly from a primary source in this review, so treat the thresholds as a question to put to your regulatory lead rather than a settled limit.

Sterility and endotoxin are the two attributes most often left until late, and both have arithmetic you can run now. The endotoxin limit formula L = K/M uses K = 5 EU/kg for most parenterals and 0.2 EU/kg for intrathecal products, with M the maximum bolus dose per kg per hour (ChemVerify’s summary of the USP bacterial endotoxins limit, calculated from the maximum human dose, 2026-04-12). The worked example is worth internalizing: 100 µg of peptide at 3 EU/mg given to a 25 g mouse yields 0.3 EU, above the 0.125 EU threshold for that dose. A limit that looks comfortable per milligram can fail at the dose you actually intend to use.

Sterility testing follows USP <71> sterility test requirements, which call for two media (Soybean-Casein Digest Medium at 20–25 °C and Fluid Thioglycollate Medium at 30–35 °C), a minimum 14-day incubation, and either membrane filtration through a ≤0.45 µm filter or direct inoculation, with direct inoculation limited to 10% of the media volume. Membrane filtration as the preferred sterility method is the regulatory gold standard where the product permits it: filtration, rinsing with inactivating agents such as lecithin, polysorbate 80 or sodium thiosulfate, then culture, with visual examination typically at days 3, 5, 7 epi 14. Viscous or non-filterable products can use direct inoculation, but plan the method choice before the GMP batch, not after.

Pou Konsèy: Build the package as a matrix, not a report. Columns for attribute, method, validation status, acceptance criterion and source of the criterion. A reviewer who can read one table and see that every Phase 1 attribute has a validated method will spend their questions on your chemistry instead of your documentation.

A capability check worth running against any supplier: can they run RP-HPLC or UPLC purity, LC-MS identity and LAL endotoxin testing against the same specification you intend to file, and can they show the validation reports for each? MOL Changes supports peptide analytical workflows across purity, identity and endotoxin testing, and the relevant question is whether the method set maps to your specification rather than whether a certificate exists. Ask for the method-by-attribute matrix and the validation summaries behind it.

Gate 5: Make the process-development decisions

By the end of this gate, the process is defined, controlled and transferable, not merely reproducible in one laboratory. Process development is what turns a repeatable synthesis into a defensible manufacturing route: fix the parameters the impurity profile depends on, write down hold times and in-process controls, and build the stability package on the conditions the ICH stability conditions an IND-enabling package is built on (ICH Q1A(R2), 2003) specify. For a drug substance intended for refrigerated storage, that means long-term storage at 5 °C ± 3 °C for 12 months and accelerated storage at 25 °C ± 2 °C / 60% RH ± 5% RH for six months; the general accelerated condition is 40 °C ± 2 °C / 75% RH ± 5% RH for six months.

Regulatory expectations are moving in the same direction. On 28 July 2026 the FDA issued 17 revised draft product-specific guidances for certain generic peptide products, updating recommendations on ANDA submissions for recombinantly, synthetically or semi-synthetically produced peptides, innate immune response testing, the FDA’s revised draft guidance on peptide impurity thresholds, higher order structure assessment and biological activity assessment, and is withdrawing its May 2021 guidance on highly purified synthetic peptide products referring to rDNA-origin listed drugs, with a revision planned in 2026. These guidances are ANDA-facing and do not govern IND-stage novel peptides, but they signal where impurity and structure expectations are heading. The failure mode is a process that passes in one facility and cannot be transferred, because the parameters controlling the impurity profile were never written down.

Pou Konsèy: Keep a single process-development decision record that lists every fixed parameter, hold time, in-process control and acceptance criterion, so a receiving site can reproduce the impurity profile rather than rediscover it.

Common mistakes that stall a peptide program

The most consequential mistake is qualifying a supplier on a single best-batch certificate of analysis. A CoA proves one lot passed; it says nothing about whether the next ten will. Ask for a lot-to-lot trend across at least three consecutive campaigns before you treat a vendor as qualified. The failure mode is silent: release testing passes on the qualification lot, then drifts past specification at the scale you actually need.

The second mistake is treating a research-scale route as scale-ready. Solid-phase synthesis stops scaling cleanly at the point where resin loading, coupling efficiency and purification yield stop moving together, and a gram-scale route tells you nothing about that boundary. Demand kilogram data, or at minimum a documented scale-up plan with the parameters that will be re-verified.

The third is assuming a modification is controlled because it was made. Making a conjugate is not the same as controlling it. Without a method that resolves the modified from the unmodified species, you cannot tell a controlled process from a lucky one.

The fourth is building the analytical package to a purity number rather than to the attribute-level method set. ICH Q2(R2) sets validation characteristics by procedure purpose, so a single purity assay cannot cover identity, potency, impurities and stability-indicating change.

The fifth is deferring stability until after the IND-enabling package is assembled. Stability defines the shelf life and the retest period, and it takes calendar time you cannot compress later. Start it while the process is still being locked.

One honest limitation: the public TwoStep record evidences the financing and the IND clearance. The readiness claims that follow from it are inferred from the framework, not disclosed by the company.

Results: what an IND-ready candidate looks like

Peptide development readiness is not a feeling about a promising sequence. It is a set of artifacts your team can hand to an investor, a partner or a regulator without a rewrite. The Series A coverage corroborating the size and date of TwoStep’s $62.5M raise (Yahoo Finance, 2026-09-10) shows capital arriving before the CMC package exists. Peptide IND-enabling studies are what close that gap.

[VISUAL: before-after, “promising sequence” (sequence, one research-scale batch, a single CoA) beside “IND-ready candidate” (reproducible lot-to-lot data, kilogram-scale evidence, a modification control table, a method-by-attribute analytical package, a defined and transferable process with a stability package)]

Structure the checklist around ICH Q6B’s specification framework: identity, purity and impurities, potency, with acceptance criteria set from process capability, method performance and product characterization. Q6B was written for biotechnological products, so treat it as a framework rather than a peptide-specific rule. The stability data should already sit at the ICH stability conditions an IND-enabling package is built on: refrigerated long-term at 5 °C ± 3 °C for 12 months, and accelerated at 25 °C ± 2 °C / 60% RH ± 5% RH for 6 months. These figures come from a summary of Q1A(R2) rather than the guideline PDF, so confirm them on the guideline page before you cite them internally. Pwodiksyon Peptid

Success looks like lot-to-lot purity inside specification, impurity thresholds at or below 0.1% with a stated justification, methods validated to ICH Q2(R2) acceptance ranges, endotoxin below the K/M limit, and sterility passing USP <71>. The stretch goal is extending the package toward higher order structure and biological activity, the assessments FDA’s 2026 draft guidances now emphasize.

Quantitative benchmarks of this kind vary by source and by program, and the figures above are drawn from vendor and legacy literature rather than audited performance data. Nothing here is regulatory advice or a substitute for your program’s own regulatory strategy.

Next steps

If the five gates above map cleanly onto your program, the next useful conversation is a technical one, not a commercial one. Bring the artifacts this framework asks for: lot-to-lot purity data across at least three consecutive lots, the modification control table with its release limits, and the method-by-attribute analytical package with its qualification status. A method-level review of those three items usually surfaces the gaps that would otherwise appear during an IND review cycle, when they are far more expensive to close.

MOL Changes publishes this article as a peptide manufacturer with a commercial interest in peptide quality standards. The framework above is drawn from primary regulatory documents and the cited sources, not from the company’s own data.

Nothing in this article constitutes regulatory advice or a substitute for your program’s own regulatory strategy. Consult a qualified professional before making regulatory or CMC decisions.

For the primary documents, read FDA’s guidance on INDs for phase 1 studies of drugs, the ICH Q2(R2) analytical validation guideline, ICH Q6B specifications for biotechnological products, ICH Q1A(R2) stability testing, and the United States Pharmacopeia chapters on sterility and bacterial endotoxins. If you would like a method-level review of your readiness package, talk to a technical expert about the specific artifacts your program has assembled.